Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1

PACE - Pacing and Clinical Electrophysiology

Volumn 37, Issue 11, 2014, Pages 1442-1447

  Huang, Duo ^a,b   Anguo, Luo ^a,c   Yue, Wen Sheng ^a,b   Yin, Lixue ^c   Tse, Hung Fat ^a   Siu, Chung Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

atrial fibrillation and stroke; CHA2DS2 VASc score

Indexed keywords

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CHADS2 SCORE; CHINESE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; CARDIOVASCULAR DISEASE; COMPLICATION; HEALTH STATUS INDICATOR; RETROSPECTIVE STUDY; RISK; STROKE;

AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; STROKE;

EID: 84920439904     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12445     Document Type: Article

References (28)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, et al., Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, et al., Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
3. Lip GY, Tse HF, Lane DA,. Atrial fibrillation. Lancet 2012; 379: 648-661.
4. Friberg L, Rosenqvist M, Lip GY,. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish Atrial Fibrillation Cohort Study. Circulation 2012; 125: 2298-2307.
5. Friberg L, Rosenqvist M, Lip GY,. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation Cohort Study. Eur Heart J 2012; 33: 1500-1510.
6. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, et al., Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ 2011; 342: d124.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, et al., Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
8. Siu CW, Jim MH, Ho HH, Miu R, Lee SW, Lau CP, Tse HF,. Transient atrial fibrillation complicating acute inferior myocardial infarction: Implications for future risk of ischemic stroke. Chest 2007; 132: 44-49.
9. Siu CW, Jim MH, Lau CP, Tse HF,. Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial. Acute Card Care 2011; 13: 196-198.
10. Siu CW, Pong V, Zhang X, Chan YH, Jim MH, Liu S, Yiu KH, et al., Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm 2009; 6: 169-173.
11. Chan KH, Leung GK, Lau KK, Liu S, Lui WM, Lau CP, Tse HF, et al., Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. World Neurosurg 2013; 84.
12. Chong BH, Chan KH, Pong V, Lau KK, Chan YH, Zuo ML, Lui WM, et al., Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. Thromb Haemost 2012; 107: 241-247.
13. Pong V, Chan KH, Chong BH, Lui WM, Leung GK, Tse HF, Pu JK, et al., Long-term outcome and prognostic factors after spontaneous cerebellar hemorrhage. Cerebellum 2012; 11: 939-945.
14. Palacio S, Hart RG,. Regarding article "guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association " Stroke. 2011; 42: e23.
15. Lau YF, Yiu KH, Siu CW, Tse HF,. Hypertension and atrial fibrillation: Epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens 2012; 26: 563-569.
16. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, et al., The registry of the German competence network on atrial fibrillation: Patient characteristics and initial management. Europace 2009; 11: 423-434.
17. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC,. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Stroke prevention in atrial fibrillation investigators. Neurology 1993; 43: 32-36.
18. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE, Strauss R, et al., Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1088-1096.
19. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL,. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1080-1087.
20. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG,. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol 1998; 31: 1622-1626.
21. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE,. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
22. Lip GY, Frison L, Grind M,. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007; 28: 752-759.
23. Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF,. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens 2011; 25: 304-310.
24. 2-VASc score of 0 or 1? Stroke 2012; 43: 2551-2555.
25. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY,. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Chest 2012; 141: 147-153.
26. Friberg L, Benson L, Rosenqvist M, Lip GY,. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study. BMJ 2012; 344: e3522.
27. 2-VASc score of 0 or 1 ?" Stroke 2013; 44: e39.
28. 2-VASc score of 0 or 1 ?" Stroke 2013; 44: e38.